Legend Biotech Corporation
LEGN
Classement en actions
#4485
Legend Biotech Corporation, through its subsidiaries, operates as a... Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Prix de l'action
$18.49
Capitalisation boursière
$3.42B
Changement (1 jour)
-2.74%
Changement (1 an)
-43.73%
Pays
US
Échange Legend Biotech Corporation (LEGN)
Catégorie
Healthcare
Revenus pour Legend Biotech Corporation (LEGN)
Revenus en Jun 2026 TTM : $1.27B
Selon les derniers rapports financiers de Legend Biotech Corporation, le chiffre d'affaires actuel de l'entreprise (TTM) est de $1.27B. En 2023, l'entreprise a réalisé un chiffre d'affaires de $285.14M une augmentation par rapport à le chiffre d'affaires de l'année 2022, qui était de $117.01M. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Legend Biotech Corporation de 2017 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $1.27B | 102.68% |
| 2024 | $627.24M | 119.97% |
| 2023 | $285.14M | 143.70% |
| 2022 | $117.01M | 70.00% |
| 2021 | $68.83M | -8.23% |
| 2020 | $75.00M | 21.36% |
| 2019 | $61.80M | 25.78% |
| 2018 | $49.13M | 108.24% |
| 2017 | $23.59M | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $12.62B | 893.02% |
US
|
|
| $2.23B | 75.25% |
US
|
|
| $15.74B | 1,138.44% |
AU
|
|
| $6.02B | 373.63% |
NL
|
|
| - | - |
CH
|
